Entresto (sacubitril/valsartan)

pCPA File Number: 20915

Negotiation Status:

Concluded with an LOI

Indication(s):

Heart failure, NYHA class II or III

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

SR0447-000

pCPA Engagement Letter Issued:

2016-06-30

Negotiation Process Concluded:

2017-03-06